Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-519 effect on blood pressure in healthy volunteers
NCT02916901Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dyslipidemia comparing CKD-519 200mg with Placebo (2 arms). Primary endpoint: Change in 24h average Systolic and Diastolic Blood Pressure at Day 14. Started Aug 2016; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02916901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916901.